Cannabis use disorder, also known as cannabis addiction, refers to compulsive cannabis use despite harmful consequences. Some key symptoms of cannabis use disorder include a strong desire to use cannabis, spending a lot of time getting, using or recovering from cannabis use, giving up important social and occupational activities due to cannabis use, and continuing to use cannabis even when it causes problems. The increasing abuse of cannabis worldwide has fueled the need for effective treatment of cannabis use disorder. Cannabis is one of the most commonly abused illicit substances globally, especially among youth. The negative health, social and economic impacts of severe cannabis dependence have highlighted the importance of developing specialized treatment options.

The global Cannabis Use Disorder treatment market size is estimated to be valued at US$1.64 Bn in 2024 and is expected to exhibit a CAGR of 9.3% over the forecast period of 2024-2031.

Increasing awareness about cannabis addiction and availability of newer treatment therapies are some of the key factors driving market growth. Additionally, legalization of medical cannabis in several countries has also increased focus on the harms of cannabis abuse.

Key Takeaways
Key players operating in the cannabis use disorder treatment market include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals. These companies have spearheaded research on novel cannabinoid-based and other therapeutic drugs for cannabis use disorder.

Key opportunities in the market revolve around development of non-addictive medications with limited side effects. Currently available therapies such as naltrexone often cause side effects like insomnia, nausea and anxiety that compromise treatment compliance. Companies are working on innovative drug delivery approaches like transdermal patches to improved efficacy and safety.

Geographically, North America dominates the global market owing to supportive regulatory environment and presence of major market players. However, Asia Pacific region is expected to witness highest growth during the forecast period driven by large patient pools in China and India and rising acceptance of cannabinoid therapies. Significant market potential also exists in Europe and Latin American countries due to growing awareness.

Market Drivers

One of the key drivers of the cannabis use disorder treatment market is growing abuse of cannabis worldwide especially among the youth population. According to various estimates, over 182 million people globally abuse cannabis each year. The negative health consequences of long-term cannabis dependence including higher risks of mental illnesses have raised concerns. This has increased the need for a safer and proven therapy to curb cannabis addiction.

Market Restrain

Limited availability and acceptability of existing therapeutics poses a major challenge to market growth. Currently available cannabis use disorder treatment options like naltrexone and counseling/behavioral therapies have low adoption due to social stigma around cannabis use and side effects of medications. Even in countries where medical cannabis is legal, its abuse remains negatively perceived which restrains patients from seeking formal care. Lack of awareness about harms and available treatment options especially in developing countries also restricts market demand to some extent.

Segment Analysis
The global Cannabis Use Disorder market is dominated by the CBD-based therapies segment owing to the proven therapeutic benefits of CBD in managing symptoms related to Cannabis addiction and withdrawal. CBD-based therapies offer advantages like no intoxicating effects, anxiety relief, better sleep, reduced cravings and withdrawal symptoms among users. The growing legalization of cannabis is also fueling research on CBD-based treatment options. The pharmaceuticals sub-segment holds prominence under the CBD therapies segment due to availability of oral drugs and pills containing standardized extracts of CBD.

Global Analysis
North America commands the major share in the global Cannabis Use Disorder market due to high cannabis usage among the population and rising legalization of medical cannabis across states like Colorado and California. According to research, about 30 million people in America have used cannabis in the past year. The region is also witnessing significant funding into development of advanced medications for cannabis use disorder. Europe ranks second driven by favorable reimbursement policies for addiction therapies and growing awareness. Asia Pacific is poised to emerge as the fastest growing regional market on account of unmet needs, increasing healthcare expenditure and expansion of key players looking to tap the opportunities.

Get more insights on this topic : https://justpaste.it/e62jy

What Are The Key Data Covered In This Cannabis Use Disorder  Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Cannabis Use Disorder 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Cannabis Use Disorder  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Cannabis Use Disorder  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Cannabis Use Disorder  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
_________________________________________________________________________